162 related articles for article (PubMed ID: 38064128)
21. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Vrontis K; Economidou SC; Fotopoulos G
Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
[TBL] [Abstract][Full Text] [Related]
22. Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G; Pusceddu S; Proto C; Macerelli M; Signorelli D; Vitali M; Ganzinelli M; Gallucci R; Zilembo N; Platania M; Buzzoni R; de Braud F; Garassino MC
Tumour Biol; 2016 Jun; 37(6):7047-57. PubMed ID: 26943800
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
[TBL] [Abstract][Full Text] [Related]
24. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
[TBL] [Abstract][Full Text] [Related]
25. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
[No Abstract] [Full Text] [Related]
27. Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status.
Thompson ED; Stelow EB; Mills SE; Westra WH; Bishop JA
Am J Surg Pathol; 2016 Apr; 40(4):471-8. PubMed ID: 26735857
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
29. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
[TBL] [Abstract][Full Text] [Related]
30. Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis.
Chen X; Huang Y; Chen F; She H; Chen X
Cancer Med; 2023 Feb; 12(4):4087-4099. PubMed ID: 36125491
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment for neuroendocrine non-small cell lung carcinoma: A cases series and a systematic review of the literature.
Jelli B; Brandão M; Mekinda Z; Durieux V; Berghmans T
Lung Cancer; 2023 Jul; 181():107232. PubMed ID: 37216840
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma.
Zhao Y; Castonguay M; Wilke D; Xu Z; Plourde M; Mulroy L; MacNeil M; Bowes D
Curr Probl Cancer; 2019 Feb; 43(1):54-65. PubMed ID: 30107896
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y; Wakuda K; Kenmotsu H; Doshita K; Kodama H; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Ko R; Ono A; Naito T; Murakami H; Sugino T; Gon Y; Takahashi T
Sci Rep; 2024 Apr; 14(1):7641. PubMed ID: 38561461
[TBL] [Abstract][Full Text] [Related]
34. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection.
Zacharias J; Nicholson AG; Ladas GP; Goldstraw P
Ann Thorac Surg; 2003 Feb; 75(2):348-52. PubMed ID: 12607637
[TBL] [Abstract][Full Text] [Related]
35. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
[TBL] [Abstract][Full Text] [Related]
36. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
[TBL] [Abstract][Full Text] [Related]
37. Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration.
Inage T; Nakajima T; Fujiwara T; Sakairi Y; Wada H; Suzuki H; Iwata T; Chiyo M; Nakatani Y; Yoshino I
Thorac Cancer; 2018 Feb; 9(2):273-277. PubMed ID: 29271588
[TBL] [Abstract][Full Text] [Related]
38. Breast metastasis and lung large-cell neuroendocrine carcinoma: first clinical observation.
Papa A; Rossi L; Verrico M; Di Cristofano C; Moretti V; Strudel M; Zoratto F; Minozzi M; Tomao S
Clin Respir J; 2017 Sep; 11(5):574-578. PubMed ID: 26365150
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report.
Wei J; Dong XF; Hu ZL; Tang S; Lu YF
Medicine (Baltimore); 2018 Dec; 97(51):e13318. PubMed ID: 30572435
[TBL] [Abstract][Full Text] [Related]
40. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
